OP37 Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)

Título:	OP37 Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)
Autores/as:	Chaparro, M García Donday, M Bode Riestra,Antonio Lucendo, A J Benítez, J M Navarro-Llavat, M Barrio, J Morales-Alvarado, V J Rivero, M Busquets, D Leo Carnerero, E Merino Ochoa, O Nantes Castillejo, O Cabrera Navarro, Pedro Van Domselaar, M Gutiérrez Casbas, A Alonso-Abreu, I Mejuto, R Fernández Salazar, L Iborra, M Martín-Arranz, M D Pineda, J R Sampedro, M J Serra Nilsson, K Bouhmidi Assakali, A Batista, L Muñoz Villafranca, C Rodríguez-Lago, I Ceballos Santos, D S Guerra, I Mañosa, M Marín Jimenez, I Vera Mendoza, I Barreiro-de Acosta, M Domènech, E Esteve, M García-Sánchez, V Nos, P Panés, J Gisbert, J P
Clasificación UNESCO:	3205 Medicina interna
Fecha de publicación:	2023
Editor/a:	Oxford University Press
Publicación seriada:	Journal of Crohn's and Colitis
Conferencia:	18th European Crohn’s and Colitis Organization Inflammatory Bowel Diseases
Resumen:	Comunicación oral al 18º congreso de la European Crohn and Colitis Organization de los resultados del ensayo multicéntrico EXIT
URI:	https://accedacris.ulpgc.es/handle/10553/137691
ISSN:	1873-9946
DOI:	10.1093/ecco-jcc/jjac190.0037
Fuente:	Journal of Crohn's and Colitis [ISSN 1873-9946], v. 17 (S_1), february 2023, pp. i50–i54
Colección:	Artículos

Vista completa